Prof. Matthew Krebs, MD, PhD

Prof. Matthew Krebs, MD, PhD

Clinical Senior Lecturer
Experimental Cancer Medicine
Honorary Consultant
Medical Oncology
The University of Manchester
Greater Manchester, UK

Related Videos

Case Study: A 42-year-old woman presented with a painful left thigh mass, a biopsy of which showed undifferentiated sarcoma. Lung nodule submitted for genomic profiling showed LMNA-NTRK gene fusion. Video

Case Study: A 42-year-old woman presented with a painful left thigh mass, a biopsy of which showed undifferentiated sarcoma. Lung nodule submitted for genomic profiling showed LMNA-NTRK gene fusion.

A 42-year-old woman presented with a painful left thigh mass, a biopsy of which showed undifferentiated sarcoma. Neoadjuvant targeted therapy, radiotherapy and chemotherapy showed no response and metastases to lung. Lung nodule submitted ...

What is your current guidance about whether and/or how and when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine? Video

What is your current guidance about whether and/or how and when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine?

What is your current guidance about whether and/or how and when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine?

NSCLC is one solid tumor where comprehensive genomic profiling can dramatically alter precision-based strategy. Can you give an example where the detection of a rare insertion altered treatment? Video

NSCLC is one solid tumor where comprehensive genomic profiling can dramatically alter precision-based strategy. Can you give an example where the detection of a rare insertion altered treatment?

As you explained, NSCLC is one solid tumor where comprehensive genomic profiling can dramatically alter a precision-based strategy. Can you provide a patient example where you have observed that the detection of a rare insertion altered the treatment choice?

Can you give us an example of a real world patient with a rare or refractory cancer whose treatment course was altered by an NGS-based FoundationOne Report? Video

Can you give us an example of a real world patient with a rare or refractory cancer whose treatment course was altered by an NGS-based FoundationOne Report?

Can you give us an example of a real world patient with a rare or refractory cancer whose treatment course was altered by an NGS-based FoundationOne Report?

What is the problematic aspect for the patient of employing a platform that fails to detect an actionable molecular alteration? Video

What is the problematic aspect for the patient of employing a platform that fails to detect an actionable molecular alteration?

What is the problematic aspect for the patient of employing a platform that fails to detect an actionable molecular alteration?

Why are current genomic testing models based on targeted sequencing ("Hot Spot") less sustainable and less effective than comprehensive NGS-based genomic profiling (CGP)? Video

Why are current genomic testing models based on targeted sequencing ("Hot Spot") less sustainable and less effective than comprehensive NGS-based genomic profiling (CGP)?

Why are current genomic testing models based on targeted sequencing (“Hot Spot”) less sustainable and less effective than comprehensive NGS-based genomic profiling (CGP) that undergird other diagnostic platforms?

How do we make sense of an NGS-based molecular profile when there appear to be a number of potentially actionable genomic alterations? How might a “molecular tumor board” be helpful? Video

How do we make sense of an NGS-based molecular profile when there appear to be a number of potentially actionable genomic alterations? How might a “molecular tumor board” be helpful?

How do we make sense of an NGS-based molecular profile when there appear to be a number of potentially actionable genomic alterations? How might a “molecular tumor board” be helpful?

What are your impressions of the ProfiLER Study and its implications for employing NGS and channeling people into trials driven by early molecular profiling? Video

What are your impressions of the ProfiLER Study and its implications for employing NGS and channeling people into trials driven by early molecular profiling?

What are your impressions of the ProfiLER Study and its implications for employing NGS and channeling people into trials driven by early molecular profiling?

How has the landscape of actionable alterations changed over time -- with respect to new fusion configurations in the setting of lung cancer, for example? And how do we approach the more rare cancers? Video

How has the landscape of actionable alterations changed over time -- with respect to new fusion configurations in the setting of lung cancer, for example? And how do we approach the more rare cancers?

How has the landscape of actionable alterations changed over time — with respect to new fusion configurations in the setting of lung cancer, for example? And how do we approach the more rare cancers?